Statins are widely used in clinics to lower cholesterol levels. Recently 
Introduction

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The product of this enzyme is mevalonate, a precursor of isoprenoid pathways in cells. Isoprenoids are building blocks of several important, sometimes essential end-products, such as: farnesylated and geranyl-geranylated proteins, ubiquinone, cholesterol, and through this latter into steroid hormones, vitamin-D, bile acids and lipoproteins
. The activity of many proteins is regulated by isoprenylation and/or addition of cholesterol [2] . Statins interfere with isoprenoid production, which will lead to altered protein synthesis [3] .
Mevalonate and cholesterol are also essential for DNA replication and cell proliferation [4] . Besides modulating the cell cycle, statins also reduce cholesterol production. Consequently, the blood low-density lipoprotein levels decrease, and this prevents arteriosclerosis. Statins have further beneficial effects on vascular walls and on platelets [3] .
The influence of statins on bone mass was first reported by Mundy et al. [5] . Lovastatin and simvastatin increased bone mass when injected subcutaneously or administered orally in rodents. It was also reported that statin therapy increased bone mass and reduced fracture risk in osteoporotic patients [6] [7] [8] . However, other studies could not show any significant difference between statin-treated patients and control [9] [10] [11] .
Statins have been shown to affect both osteoclast and osteoblast cells at different levels. An inhibitory effect of statins on bone resorption was demonstrated recently by several research groups [12, 13] . They suggested that statins act on osteoclasts similarly to bisphosphonates, by the inhibition of farnesylation and geranylgeranylation of proteins, leading to inactivation of osteoclasts through cytoskeletal changes.
In addition, statins appear to enhance osteoblast function. [14] . Pitavastatin [16, 17] .
Maeda et al. reported that statins induced the gene expression of several osteoblast markers (BMP-2, VEGF, ALP, COL1, BSP, OCN) in a pre-osteoblastic mouse cell line
There are few reports regarding the effect of statins on primary human MSCs, and the results are rather controversial. Fluvastatin and simvastatin induced osteogenic differentiation in two separate studies [18, 19] . On the contrary, Lee et al. found that fluvastatin and lovastatin promoted neuroglial, but not osteoblastic differentiation of hMSCs [20] . There is also disagreement between studies on rodent MSCs [21, 22] .
In 
Materials and methods
Isolation and expansion of MSCs
Experimental conditions
The cells were seeded in 24- 
Alkaline phosphatase activity assay
Cell monolayers were extracted with 1% Triton-X for 3 hrs at 4Њ C as previously described [27] . The extracts were frozen at Ϫ20Њ C until assayed. 
Real-time PCR
BMP-2 expression
BMP-2 is a versatile growth factor, often associated with osteoblast differentiation. Its expression was up-regulated by statins at day 4 compared to non-induced control (Fig. 2) . In 
Statins suppress ALP activity and expression
ALP activity is another well-known marker for osteoblastic differentiation [30] . Its activity was inhibited by statins in a dosedependent manner (Fig. 3A) . When we further investigated 1 and 5 M statins, we found a significant suppression in all patients at both concentrations (Fig.  3B) . Dexa is known to promote osteoblastic differentiation in vitro; consequently, a marked increase in ALP activity was detected in the cells treated with dexa.
The ALP gene expression levels were also measured within the different groups (Fig. 3C) 
DNA content and cell viability
Lovastatin and simvastatin-treatment lowered DNA content in a dose-dependant manner at day 18 (Fig. 4A) . The initial, low cell density and 10% serum in the medium permitted MSC proliferation, as confirmed by MTT assay (Fig. 4B) . When the samples were treated with 5 M statins, the cell number only marginally increased by day 4, followed by a significant drop from day 11 to day 18. Lower statin concentration (1 M) caused a slower increase in cell number compared with non-induced control. 
Fig. 1 Ca-45 incorporation rates. (A) Dose-dependent increase of Ca-45 incorporation by statins at day 18. C, non-induced control; D, dexa; L, lovastatin; S, simvastatin. The numbers next to letters represent concentrations in M. 1 donor, the error bars show S.D. of triplicates (experimental error). (B) Calcium incorporation rates relative to non-induced control after 25 days, on a logarithmic scale (3-9 donors, triplicates). C, non-induced control
Fig. 2 BMP-2 expression. Relative amount of BMP-2 mRNA in different treatment groups at three time-points (distinguished by greyscale shading). C, non-induced control; D, dexa; L1, 1 M lovastatin; L5, 5 M lovastatin; S1, 1 M simvastatin; S5, 5 M simvastatin. Each bar represents a mean value of 2-6 experiments (n ϭ 2-6). All values are relative to day 4 non-induced control of the respective experiment, and are plotted on a logarithmic scale. The error bars span 1 S.D.
Von Kossa staining
Both 5 M statins and dexamethasone caused mineral deposition, which was stained by von Kossa's method after 25 days of culture (Fig. 5). The staining appeared very similar on the large scale, however, the microscopic morphology of these deposits was different: in the dexamethasone-treated samples mineralization was visible in the extracellular matrix and around the cells, whereas the statins caused strong staining only along the cell membranes.
Apoptotic staining
Statins at 5 M clearly changed cell morphology already by day 4. The type of cell death (apoptotic or necrotic) was determined by
Annexin-V-propidium-iodide combined staining. Intense Annexin-V staining was observed in 5 M statin samples at day 18 (Fig. 6) . The stained cells were large, round and the cell membranes were rough.
Discussion
In this study, we investigated the effect of three statins on primary human MSCs. It has been suggested that statins may promote osteoblastic differentiation of MSCs in mouse and human cell line [15, 21] . These assumptions were mainly based on the increase in the mRNA expression of BMP-2. This was also observed in our experiments. However, other pronounced alterations, especially in cell morphology, suggest to us that prolonged exposure to statins might have a cytotoxic effect on most of the human MSCs. drogenic and neuronal differentiation as well [20] . ALP activityanother important marker of osteoblast differentiation -was significantly decreased. This inhibitory effect was also observed at the ALP gene expression level throughout the whole culture period. The extent of down-regulation was comparable to the decrease of activity, so statins probably regulate ALP activity at the transcription level.
Fig. 3 Alkaline phosphatase. (A) Dose-dependent suppression of ALP activity by statins at day 18. C, non-induced control; D, dexa; L, lovastatin; S, simvastatin. The numbers next to letters represent concentrations in M. 1 donor, the error bars show S.D. of triplicates (experimental error). (B) ALP activity was measured with a para-nitrophenylphosphate assay at day 11. The amount of product was normalized to DNA, and compared with the activity of the non-induced control. C, non-
These results are in contrast with the recent data of Baek et al. [19] . In their study, the ALP activity was elevated during the first 6 days. Human MSCs were isolated with the same method in both 
